Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171418
Status:
COMPLETED
Last Update Posted:
2008-01-28
First Post:
2005-09-12
Brief Title:
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease GERD in Patients With Incomplete Response to Proton Pump Inhibitors PPIs
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease GERD in Patients With Incomplete Response to Proton Pump Inhibitors PPIs
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None